SAB Biotherapeutics, Inc. (SABS) Financials

SABS Assets vs Liabilities
DateAssetsLiabilities
June 30, 2026 238.2 million 23.4 million
March 31, 2026 248.5 million 21.2 million
Dec. 31, 2025 172.8 million 21.3 million
Sept. 30, 2025 183.4 million 18.4 million

SABS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
June 30, 2026 -26.7 million 12.7 million
March 31, 2026 -15.3 million 5.5 million
Dec. 31, 2025 -17.7 million 3.2 million
Sept. 30, 2025 -13.1 million 187813

SABS Net Income

No data available :(

SABS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
June 30, 2026 102.6 million 4.5 million 5.1 million
March 31, 2026 107.4 million - 6.2 million
Dec. 31, 2025 96.6 million - 5.0 million
Sept. 30, 2025 110.9 million - 6.2 million

SABS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
June 30, 2026 79.8 million
March 31, 2026 53.6 million
Dec. 31, 2025 61.3 million
Sept. 30, 2025 77.9 million

SABS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
June 30, 2026 2.6 million 16.2 million 7.2 million -
March 31, 2026 983260 13.4 million 5.9 million -730965
Dec. 31, 2025 933155 10.7 million 5.0 million -
Sept. 30, 2025 3 8.9 million 3.7 million -

SABS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
June 30, 2026 - -
March 31, 2026 - 752670
Dec. 31, 2025 - 763299
Sept. 30, 2025 - 765469

SABS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

SABS

Price: $3.77

52 week price:
1.85
5.15

Earnings Per Share: 0.24 USD

P/E Ratio: 15.67

Exchange: NCM

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 35000

Market Capitalization: 342.1 million

Links: